The story has been updated to provide additional details and comments from Adaptive Biotechnologies' CEO, Chad Robins.

NEW YORK (GenomeWeb News) – Immune sequencing services company Adaptive Biotechnologies has raised $5 million toward a targeted $20 million financing round.

In a Form D filed with the US Securities and Exchange Commission recently, it said that the securities offered were in the form of equity. Adaptive Bio's CEO Chad Robins told GenomeWeb Daily News that that the $5 million was the first tranche of a Series C round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.